Physician profile
Peter E Eupierre
NPI 1528069481
$10,633.80
in general payments reported to CMS, 2019-2025
35 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $966 · 2021: $2,243 · 2022: $1,595 · 2023: $2,188 · 2024: $2,028 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,389.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,584.05 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $1,323.34 | 2019-2021 | |
| Lilly USA, LLC | $1,242.75 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $1,105.70 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $887.27 | 2019-2024 | Jardiance, Ofev, Cyltezo |
| Pfizer INC. | $606.78 | 2019-2025 | |
| Amgen INC. | $589.89 | 2019-2024 | Repatha, Otezla, Krystexxa |
| Novartis Pharmaceuticals Corporation | $457.54 | 2019-2024 | |
| Janssen Biotech, INC. | $387.05 | 2021-2024 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $358.37 | 2019-2025 | Eliquis, Orencia |
| Merck Sharp & Dohme LLC | $297.67 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Medtronic, INC. | $235.83 | 2021 | |
| Horizon Therapeutics Plc | $225.03 | 2021-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $201.93 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $194.53 | 2021-2024 | Saphnelo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $155.61 | 2023-2024 | Cimzia, Bimzelx |
| Sobi, INC | $119.85 | 2021-2024 | |
| Sandoz INC. | $92.88 | 2023-2024 | Hyrimoz |
| Medtronic Vascular, INC. | $74.01 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.59 | 2022 | |
| Lucid Diagnostics INC. | $58.18 | 2023 | |
| Glaxosmithkline, LLC. | $50.15 | 2020-2023 | Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $47.26 | 2020-2021 | |
| Exact Sciences Corporation | $47.09 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $35.27 | 2020-2021 | |
| Sanofi Pasteur INC. | $24.88 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.12 | 2023 | Gvoke Hypopen |
| Actelion Pharmaceuticals US, INC. | $22.53 | 2024 | Uptravi, Opsumit |
| Alexion Pharmaceuticals, INC. | $21.57 | 2023 | Strensiq |
| Biohaven Pharmaceuticals, INC. | $21.57 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.39 | 2022 | |
| Phadia US INC. | $17.70 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.15 | 2021 | |
| Seqirus USA INC | $13.37 | 2022 | |
| Hologic Sales and Service, LLC | $11.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Eupierre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.